Followers | 65 |
Posts | 1221 |
Boards Moderated | 0 |
Alias Born | 04/02/2020 |
Wednesday, January 20, 2021 11:47:44 PM
Thanks for bringing to everyone’s attention a real-time example (https://www.eurekalert.org/pub_releases/2021-01/b-ntf011921.php) of what some on this board have forgotten. The primary objective for a steering committee like the DSMC is to assure the safety for the patients in a clinical trial. Their oversight determines if a clinical trial continues or is halted based on safety and/or efficacy.
When a trial is not demonstrating a trend towards meeting its primary endpoint, the DSMC will work with the trial sponsor to make adjustments (increase trial size, modify or change primary endpoint, etc...). We’ve seen numerous examples of this recently. Or, in a case like tocilizumab, when far too many deaths occur in the treatment arm, a trial is halted to insure the safety of future participants.
Some are trying their damndest to convince us those two reviews performed by the DSMC with CYDY should not be considered positive when we’ve seen other trials with endpoint changes and/or halted like was just described. They’ve double-down and gone dug their grave even deeper by telling you the results won’t even be turned over for review to the FDA. For that I’ll just use the words of our 46th President, “Will you shut up, man?”
CytoDyn, with it’s lead drug leronlimab, is the only company... let me repeat that... CytoDyn is the only company to successfully complete a Phase 3 randomized clinical trial for severe-to-critically ill Covid-19 patients with mortality as an endpoint!!! Wait for it... DON’T BLINK
Then I see this article passed around (http://www.ipharminc.com/new-blog/2021/1/20/the-rise-of-coronavirus-variants-early-signs-of-immune-escape) along with the following quote: “If covid is a lab synthesized virus it was manufactured to override any single known therapeutic. Including the worthless '90s drug leronlimab. Therapeutics are failing to reach primary endpoints left and right. Time for a new approach against covid.“
I’m so glad this was brought up as a discussion topic... First off, it sounded like the writer was asking a question which somehow seemed to turn into a declaration based on expert analysis.. I’m not sure... but, I’ll just assume it’s a question... With that in mind, I will repeat again, CytoDyn, with it’s lead drug leronlimab, is the only company to successfully complete a Phase 3 randomized clinical trial for severe-to-critically ill Covid-19 patients with mortality as an endpoint!!! You don’t have to be a virologist to know that a drug with a mortality as a primary endpoint complete two DSMC reviews with no changes to know that means the drug is working as it was intended in the trial design.
If it’s important for the writer to hear from a virologist, the answer to the question was addressed by Dr. Bruce Patterson (
If you want an abbreviated version of the core message from Dr. Patterson’s TEDx talk as it relates to Covid-19 you can find it here... (
Before it even gets started... I don’t want to hear any comments that say Dr. Patterson’s research is biased... #1 Dr. Patterson is a very distinguished and well respected virologist and #2 his research and manuscript as it relates to leronlimab and Covid-19 has been published after peer review.
So, you ask me what do you say when you’re told leronlimab is a water shot, that it will never work in Covid, and/or that CytoDyn is a fraud? My answer is easy... ask yourself or someone you trust who understands the science... “Does the science demonstrate that leronlimab blocks CCR5 and Rantes, that it brings back T-cell functions/#’s, and that it decrease the viral plasma load?” Everything else is noise in my opinion and, at the end of the day, I stick with the science behind leronlimab!!!
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:48:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:46:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/17/2024 09:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/15/2024 09:16:35 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/11/2024 01:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 09:15:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/30/2024 09:01:16 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM